Evidence map›Paper›PMID 20533006›Full record

ArticleHead and neck pathology2010

Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.

Indraneel Bhattacharyya, Hardeep K Chehal, Donald M Cohen, Samer Z Al-Quran

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Head and neck pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Diffused mixed B-cell non-Hodgkin lymphoma of mandible.Journal of oral and maxillofacial pathology : JOMFP · 2020
    Article
  8. Article
  9. Article
  10. Physical torment: A predisposition for diffuse B-cell lymphoma.Journal of oral and maxillofacial pathology : JOMFP · 2019
    Article
  11. Evaluation of a case of diffuse large B-cell lymphoma.Journal of oral and maxillofacial pathology : JOMFP · 2019
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Diffuse Large B-Cell Lymphoma of Maxilla - A Case Report of Late Relapse.Journal of clinical and diagnostic research : JCDR · 2016
    Article
  17. Article
  18. Diffuse large B - Cell lymphoma involving the maxilla in a minor.Journal of clinical and diagnostic research : JCDR · 2014
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Indraneel BhattacharyyaDepartment of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL 32610, USA. ibhattacharyya@dental.ufl.edu
Hardeep K Chehal
Donald M Cohen
Samer Z Al-Quran
Florida College · USCreighton University · USUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary lymphomas of the oral cavity are rare and the most frequent type is diffuse large B-cell lymphoma (DLBCL). Recently, several reports have highlighted the value of classifying DLBCL into prognostically important subgroups, namely germinal center B-cell like (GCB) and non-germinal center B-cell like (non-GCB) lymphomas based on gene expression profiles and by immunohistochemical expression of CD10, BCL6 and MUM-1. GCB lymphomas tend to exhibit a better prognosis than non-GCB lymphomas. Studies validating this classification have been done for DLBCL of the breast, CNS, testes and GI tract. Therefore we undertook this study to examine if primary oral DLBCLs reflect this trend. We identified 13 cases (age range 38-91 years) from our archives dating from 2003-09. IHC was performed using antibodies against germinal center markers (CD10, BCL6), activated B-cell markers (MUM1, BCL2) and Ki-67 (proliferation marker). Cases were sub-classified as GCB subgroup if CD10 and/or BCL6 were positive and MUM-1, was negative and as non-GCB subgroup if CD10 was negative and MUM-1 was positive. Immunoreactivity was noted in 2/13 cases for CD10, in 12/13 for BCL6, in 8/13 for MUM-1, and in 6/13 for BCL2. Therefore, 8/13 (58%) were sub-classified as non-GCB DLBCLs and 5/13 (42%) as GCB subgroup. All tumors showed frequent labeling with Ki-67 (range 40-95%). Four of the 8 patients with non-GCB subgroup succumbed to their disease, with the mean survival rate of 16 months. Two patients in this group are alive, one with no evidence of disease and another with disease. No information was available for the other 3 patients in this group. Four of the 5 patients in the GCB subgroup were alive with no evidence of disease and one patient succumbed to complications of therapy and recurrent disease after 18 months. In conclusion, our analysis shows that primary oral DLBCL predominantly belongs to the non-GCB subgroup, which tends to exhibit a poorer prognosis. These findings could allow pathologists to provide a more accurate insight into the potential aggressive behavior and poorer prognosis of these lymphomas.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalDNA-Binding ProteinsFatal OutcomeFemaleGerminal CenterHumansImmunohistochemistryInterferon Regulatory Factor-4Interferon Regulatory FactorsKi-67 AntigenLymphoma, Large B-Cell, DiffuseMaleBCL6 protein, humanBiomarkers, TumorDNA-Binding ProteinsInterferon Regulatory Factor-4Interferon Regulatory FactorsKi-67 AntigenNeprilysinProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6

Identifiers

PMID20533006
PMCPMC2923304
OpenAlexW2047672735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.